Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?
Clinical cancer registry data
Neoadjuvant chemotherapy
Time to systemic therapy
Triple negative breast cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
07
06
2023
accepted:
28
06
2023
medline:
31
8
2023
pubmed:
7
7
2023
entrez:
7
7
2023
Statut:
ppublish
Résumé
For patients with triple negative breast cancer (TNBC), the optimal time to initiate neoadjuvant chemotherapy (TTNC) is unknown. This study evaluates the association between TTNC and survival in patients with early TNBC. A retrospective study using data from of a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018 registered in the Tumor Centre Regensburg was performed. Data included demographics, pathology, treatment, recurrence, and survival. Interval to treatment was defined as days from pathology diagnosis of TNBC to first dose of neoadjuvant chemotherapy (NACT). The Kaplan-Meier and Cox regression methods were used to evaluate the impact of TTNC on overall survival (OS) and 5 year OS. A total of 270 patients were included. Median follow up was 3.5 years. The 5-year OS estimates according to TTNC were 77.4%, 66.9%, 82.3%, 80.6%, 88.3%, 58.3%, 71.1% and 66.7% in patients who received NACT within 0-14, 15-21, 22-28, 29-35, 36-42, 43-49, 50-56 and > 56 days after diagnosis. Patients who received systemic therapy early had the highest estimated mean OS of 8.4 years, while patients who received systemic therapy after more than 56 days survived an estimated 3.3 years. The optimal time interval between diagnosis and NACT remains to be determined. However, starting NACT more than 42 days after diagnosis of TNBC seems to reduce survival. Therefore, it is strongly recommended to carry out the treatment in a certified breast center with appropriate structures, in order to enable an adequate and timely care.
Identifiants
pubmed: 37418056
doi: 10.1007/s00432-023-05060-y
pii: 10.1007/s00432-023-05060-y
pmc: PMC10465651
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11941-11950Informations de copyright
© 2023. The Author(s).
Références
J Surg Oncol. 2020 Dec;122(8):1761-1769
pubmed: 33125715
Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617
pubmed: 31217629
Clin Breast Cancer. 2018 Oct;18(5):e841-e850
pubmed: 30146351
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Oncologist. 2020 Sep;25(9):749-757
pubmed: 32431013
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Ann Surg Oncol. 2013 Jun;20(6):1880-5
pubmed: 23292484
Breast Cancer Res Treat. 2019 Aug;177(1):137-143
pubmed: 31119565
Cancer. 2008 Nov 15;113(10):2638-45
pubmed: 18833576
J Thorac Dis. 2018 May;10(5):2837-2841
pubmed: 29997947
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Lancet Oncol. 2019 Jul;20(7):e390-e396
pubmed: 31267973
J Clin Oncol. 2014 Mar 10;32(8):735-44
pubmed: 24470007
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Eur J Surg Oncol. 2017 Apr;43(4):613-618
pubmed: 27793416
Lancet Oncol. 2018 Jan;19(1):27-39
pubmed: 29242041
Cancers (Basel). 2022 Aug 10;14(16):
pubmed: 36010854
Surg Oncol Clin N Am. 2018 Jan;27(1):141-153
pubmed: 29132557
Ann Surg Oncol. 2016 May;23(5):1515-21
pubmed: 26678405
J Clin Oncol. 2021 May 1;39(13):1485-1505
pubmed: 33507815
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Oncologist. 2011;16 Suppl 1:1-11
pubmed: 21278435
J Clin Oncol. 2022 May 20;40(15):1696-1698
pubmed: 35417251
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Cancer Treat Rev. 2021 Nov;100:102283
pubmed: 34530283
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
Breast J. 2020 Apr;26(4):625-629
pubmed: 31513322
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
JAMA Oncol. 2016 Mar;2(3):322-9
pubmed: 26659132
Oncologist. 2013;18(2):123-33
pubmed: 23404817